Articles related to CARDIOVASCULAR EVENTS

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

In this multicenter trial of 901 patients with asymptomatic severe aortic stenosis, early TAVR intervention reduced the composite endpoint of death, stroke, or unplanned cardiovascular hospitalization by 50% compared to clinical surveillance.

Clinical research demonstrates that erythritol consumption increases blood levels by more than 1,000 times and enhances platelet responsiveness in healthy volunteers, potentially elevating cardiovascular risk in susceptible populations.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.

Bempedoic acid reduced major adverse cardiovascular events by 13% compared to placebo in statin-intolerant patients, with efficacy comparable to statins when normalized for LDL-C reduction.

The ABYSS trial questions the safety of interrupting long-term beta-blocker treatment in patients with a history of uncomplicated myocardial infarction, finding that discontinuation was not noninferior to continuation.